Scheinman J I, Fish A J, Matas A J, Michael A F
Am J Pathol. 1978 Jan;90(1):71-88.
Immunofluorescent studies have demonstrated that actomyosin (AMY) is present in the mesangium in a restrictive pattern, whereas fibroblast surface antigen (FSA) has a more extensive mesangial distribution. Antibody to glomerular basement membrane (GBM) is localized to the GBM. One hundred ninety-six tissue samples, including 17 from normal subjects, 94 from patients with primary renal diseases, and 85 from transplanted kidneys, were examined for changes in distribution of AMY, FSA, and GBM antigens. The distribution of AMY and FSA in the mesangium is markedly increased in width in patients with diabetic nephropathy, and the GBM is thickened. AMY and FSA are mildly increased in patients with glomerulonephritis and GBM is normal. Patients with membranoproliferative glomerulonephritis (MPGN) show a loss of all glomerular antigens. Increased mesangial AMY was found in 12 of 37 transplanted kidneys in diabetic patients vs 4 of 33 nondiabetics 0 to 4 years after transplantation (P < 0.025). This difference is more notable at 2 to 4 years, with 5 of 9 diabetics showing increased AMY vs 0 of 6 nondiabetic patients (P < 0.0005). In MPGN, 5 of 8 tissues showed decreased mesangial AMY vs 3 of 36 diabetic patients (P < 0.0005) and 1 of 32 patients with other glomerulopathies (P < 0.0005). GBM thickening is not associated with specific pretransplant diseases. In transplanted kidneys, the pattern of FSA is dissociated from that of AMY: over half of all patients have increased FSA, even when AMY is normal. Whether this unique finding in transplanted kidneys reflects an increase in the synthesis of FSA by mesangial cells or the failure to clear this (circulating) antigen from the mesangial matrix is unknown.
免疫荧光研究表明,肌动球蛋白(AMY)以局限性模式存在于系膜中,而成纤维细胞表面抗原(FSA)在系膜中的分布更为广泛。抗肾小球基底膜(GBM)抗体定位于GBM。对196份组织样本进行了检测,其中包括17份来自正常受试者、94份来自原发性肾脏疾病患者以及85份来自移植肾的样本,以观察AMY、FSA和GBM抗原分布的变化。糖尿病肾病患者系膜中AMY和FSA的分布宽度显著增加,且GBM增厚。肾小球肾炎患者的AMY和FSA轻度增加,GBM正常。膜增生性肾小球肾炎(MPGN)患者的所有肾小球抗原均缺失。糖尿病患者移植肾中,37例中有12例在移植后0至4年系膜AMY增加,而非糖尿病患者33例中有4例增加(P<0.025)。这种差异在2至4年时更为明显,9例糖尿病患者中有5例AMY增加,而6例非糖尿病患者中无1例增加(P<0.0005)。在MPGN中,8份组织中有5份系膜AMY减少,而糖尿病患者36例中有3例(P<0.0005),其他肾小球病患者32例中有1例(P<0.0005)。GBM增厚与移植前的特定疾病无关。在移植肾中,FSA的模式与AMY的模式不一致:超过半数的患者FSA增加,即使AMY正常。移植肾中的这一独特发现是反映系膜细胞FSA合成增加还是未能从系膜基质中清除这种(循环)抗原尚不清楚。